Recent Developments in Triazolopyrimidine-based Cancer Therapeutics: A Mini Review

The triazolopyrimidine ring has emerged as a ubiquitous and highly versatile structural motif found in a wide array of biologically active compounds. Owing to its unique fused heterocyclic architecture, this core is capable of engaging in diverse intermolecular interactions with biological targets. Such features have placed triazolopyrimidines as a particularly attractive scaffold in contemporary anticancer drug discovery. Over the past decade, and more conspicuously in the last five years, this framework has gained substantial attention due to its ability to modulate multiple cancer-relevant pathways with notable potency and selectivity. Strategic structural modifications, such as derivatization with appropriate substituents, hybridization with other pharmacophores, and metal complexation, have significantly enhanced their pharmacological profiles. These rational approaches not only improve efficacy and selectivity but also address key challenges, such as drug resistance, bioavailability, and off-target toxicity. Recent advances have also highlighted the potential of both organic derivatives and inorganic triazolopyrimidine-based complexes, particularly in the context of metallodrugs, where coordination with transition metals has led to improved cytotoxicity and novel mechanisms of action. Collectively, these developments highlight the promise of triazolopyrimidine scaffolds in transforming the current landscape of cancer therapy. This review critically summarizes and discusses the progress made in the design, synthesis, and anticancer evaluation of triazolopyrimidine-based organic and inorganic scaffolds reported in the scientific literature over the past five years, with an emphasis on their mechanisms of action and future therapeutic prospects.